Alexander Cumbo
President, CEO & Director
All right. Thank you very much. My name is Bo Cumbo, representing Solid Biosciences, and thank you, Goldman Sachs for the invitation. So we’re going to be making a few forward-looking statements. Please take time to look at the cautionary note regarding forward-looking statements and take the time to read through it. As you know, this is science, and it’s hard to predict sometimes, but I’ll be doing my best to look forward.
So here’s the pipeline of Solid Biosciences. It’s a very robust pipeline. We’re going to be up top Duchenne and FA, followed by a maturing cardiac pipeline that is one of the deepest cardiac pipelines in the gene therapy space. Today, I’m going to be really focused in on Duchenne and FA, and I’ll touch a little bit on our platform. As mentioning before, we have 2 programs that are already in the clinic as well as our Capsid platform and manufacturing platform. Our program, our novel next-generation program for Duchenne called 003 is currently in Phase III clinical trials as well as we’re continuing to enroll in our Phase I/II INSPIRE program, which we’ve already dosed 51 patients as of this week.
We also have the first-in-class dual route administration for Friedreich’s ataxia targeting not only the cardiac but CNS manifestations of disease is another program, just like the 003 program for Duchenne that we’re extremely excited about. And our Capsid library is becoming very robust. We do have Polaris out there. We have 50-plus agreements with academic labs as well as small companies. But by the end of the year, we should have multiple other capsids that
